Effects of entecavir and tenofovir on renal function in patients with hepatitis B virus-related compensated and decompensated cirrhosis

Gut and Liver

Volumn 11, Issue 6, 2017, Pages 828-834

  Park, Jihye ^a   Jung, Kyu Sik ^a   Lee, Hye Won ^a,b   Kim, Beom Kyung ^a,b   Kim, Seung Up ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b   Han, Kwang Hyub ^a,b   Park, Jun Yong ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Entecavir; Fibrosis; Hepatitis B; Renal safety; Tenofovir

Indexed keywords

DIURETIC AGENT; ENTECAVIR; TENOFOVIR; ANTIVIRUS AGENT; GUANINE;

ADULT; ARTICLE; CHRONIC HEPATITIS B; COHORT ANALYSIS; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIABETES MELLITUS; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SOUTH KOREA; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG EFFECT; EVALUATION STUDY; GLOMERULUS FILTRATION RATE; HEPATITIS B VIRUS; KIDNEY; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; FEMALE; GLOMERULAR FILTRATION RATE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KIDNEY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; SEOUL; TENOFOVIR; TREATMENT OUTCOME;

EID: 85031292742     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl16484     Document Type: Article

References (27)

1. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-1290.
2. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003;37:233-243.
3. Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971;2:234-237.
4. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
5. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455.
6. Ahn SH, Heo J, Park JY, et al. A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy. J Gastroenterol Hepatol 2016;31: 865-871.
7. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49(5 Suppl):S185-S195.
8. Quesada PR, Esteban LL, García JR, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm 2015;37:865-872.
9. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-185.
10. Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1317-1325.
11. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
12. Hwang HS, Park CW, Song MJ. Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology 2015;62:1318-1320.
13. Lee S, Park JY, Song K, et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver 2015;9:776-783.
14. Barrios A, García-Benayas T, González-Lahoz J, Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 2004;18:960-963.
15. James CW, Steinhaus MC, Szabo S, Dressier RM. Tenofovir-related nephrotoxicity: case report and review of the literature. Pharmacotherapy 2004;24:415-418.
16. Jang JW, Choi JY, Kim YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015;61:1809-1820.
17. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75.
18. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307:1941-1951.
19. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-893.
20. Ahn SS, Chon YE, Kim BK, et al. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-na?ve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. Clin Mol Hepatol 2014;20:261-266.
21. Najjar Z, Gupta L, Pritchard-Jones J, et al. A survey of Sydney general practitioners' management of patients with chronic hepatitis B. Med J Aust 2016;204:74.
22. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-430.
23. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132-143.
24. Yip B, Chaung K, Wong CR, et al. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci 2012;57:3011-3016.
25. Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:941-946.
26. Ha NB, Ku K, Ha NB, Chaung KT, Trinh HN, Nguyen MH. Renal function in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or entecavir monotherapy: a matched case-cohort study. J Clin Gastroenterol 2015;49:873-877.
27. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010;51:73-80.